ABSTRACT When the metabolism of a drug is competitively or noncompetitively inhibited by another drug, the degree of in vivo interaction can be evaluated from the [I] u /K i ratio, where [I] u is the unbound concentration around the enzyme and K i is the inhibition constant of the inhibitor. In the present study, we evaluated the metabolic inhibition potential of drugs known to be inhibitors or substrates of cytochrome P450 by estimating their [I] u /K i ratio using literature data.
INTRODUCTION As fractions of human tissues such as
human liver microsomes and human hepatocytes have become more easily available for in vitro studies, attempts have been made to quantitatively predict in vivo drug metabolism or drug interactions in humans from in vitro data. [1] [2] [3] In the case of a competitive or noncompetitive inhibition of drug metabolism, the degree of in vivo interaction can be evaluated from the [I] u /K i ratio, where [I] u is the unbound concentration around the enzyme and K i is the in vitro inhibition constant of the inhibitor.
In clinical situations, the substrate concentration is usually much lower than Km and the maximum degree of interaction (R = area under the curve [AUC] (+ inhibitor) / AUC (control)) is expressed as R = 1 + [I] u /K i , assuming that the substrate is eliminated from the body only by the inhibited pathway. 1 Although K i values can be determined by kinetic analyses of in vitro data using human liver microsomes or recombinant enzymes, it is usually impossible to directly measure [I] u in humans.
In the case of drugs that are transported into the liver by passive diffusion, [I] u may be assumed to be equal to the unbound concentration in the liver sinusoid at steady-state. In order to avoid a false-negative prediction due to underestimation of [I] u , we have proposed the use of the maximum unbound concentration at the inlet to the liver, where the blood flow from the hepatic artery and portal vein meet ([I] in,max,u ), as the maximum value of [I] u . 1, 4 We have succeeded in semiquantitative prediction of several cases of drug interactions using this [I] in,max,u value as [I] u . 1, 5 This method was thus proposed to be useful for predicting the maximal degree of inhibition. 1, 4 In the present study, the metabolic inhibition potential of a number of drugs known to be inhibitors or substrates of cytochrome P450 (CYP) has been evaluated by estimating their [I] u /K i ratio using literature data. The maximum concentration in the circulating blood ([I] 
MATERIALS AND METHODS
Using the values of K i and pharmacokinetic data reported in the literature, the [I] u /K i ratios were calculated for a number of drugs known to be inhibitors or substrates of human CYP enzymes. Inhibitors and substrates of various human CYP isozymes were selected mainly from the reviews or textbooks. 3, 6, 7 K i values evaluated using human liver microsomes (or recombinant human CYP isozymes) were collected together with the inhibition type and the CYP isozyme involved. To avoid the underestimation of in vivo interactions, the smallest K i value was used in the analysis if more than 2 values of K i were reported for a drug. If no information of K i was available, Km (Michaelis constant) was used instead of K i . Calculation was not conducted if the inhibition type was other than competitive or noncompetitive inhibition.
According to the perfusion model shown in Figure 1 , the maximum concentration of inhibitor at the inlet to the liver ([I] in,max ) can be calculated as follows [1] [2] [3] [4] :
where ka is the absorption rate constant, Fa is the fraction absorbed from gut to the portal vein, and Qh is the hepatic blood flow rate. Using the unbound fraction in the blood (fu), [I] in,max,u can be obtained as follows: The value of [I] max after a single oral administration of a therapeutic dose was estimated from reported plasma concentrations assuming a linear pharmacokinetics. To avoid underestimation of interactions, the maximum value of [I] max or fu was used if the parameter was reported with a range. The values of ka, Fa, Qh, and R B (blood-to-plasma concentration ratio) were assumed to be 0.1 min -1 (a first-order rate constant reported for the gastric emptying 8 ), 1, 1610 mL/min, and 1, respectively.
In the case of drugs that inhibit more than 2 CYP isozymes, the [I] u /K i ratios were calculated for each CYP isozyme. When any metabolites of the drug were also reported to inhibit the enzyme, the [I] in,u / K i ratio was calculated for both the parent drug and the metabolite(s), and the largest value was used in the analysis.
Reports of in vivo interactions in clinical studies involving the investigated drugs were also examined, and the degree of the interaction was expressed as percentage increase in the area under the concentration-time curve (AUC) of a co-administered substrate of the corresponding CYP isozyme. Although this may result from using the maximum possible values of 0.1 min -1 and 1 for ka and Fa, respectively, which may vary among the drugs, this finding suggests that the absorption term should not be ignored to avoid the underestimation of drug interactions.
RESULTS AND DISCUSSION
In Table 2 , the calculated [I] in,max,u /K i ratios were classified according to the CYP isozyme involved. Figures in this table indicate the number of the inhibitor-CYP isozyme combinations. CYP3A4 and CYP2D6 were found to be inhibited by the largest number of drugs, followed by CYP1A2 and. No clear difference was observed in the distribution of [I] in,max,u /K i ratios among the CYP isozymes involved. Table 3 shows the relationship between the calculated [I] in,max,u /K i ratio and the degree of in vivo interaction, indicated as the increase in the AUC of the coadministered substrates. Nine of the investigated drugs were reported not to cause any interactions with the substrates of the corresponding CYP isozymes in vivo. Reports of in vivo interactions were not found for more than half of the drugs investigated, but the [I] in,max,u /K i ratios of most of the drugs in this group were calculated to be less than 0.25. As shown in Table 3 , the [I] in,max,u /K i ratio was calculated to be less than 0.25 for about half of the drugs investigated and no in vivo drug-drug interactions have been reported or "no interaction" was reported in clinical studies for about 80% of such drugs. In contrast, the [I] in,max,u /K i ratio was calculated to be greater than 2.0 for about 16% of the drugs investigated, and about 80% of such drugs were reported to cause in vivo drug-drug interactions in which more than a 2-fold increase was observed in the AUC of the coadministered substrate of the corresponding CYP isozyme. Moreover, the [I] in,max,u /K i ratio was calculated to be greater than 2.0 for all of the drugs reported to cause in vivo interactions with more than a 5-fold increase in the AUC. These findings indicate that the degree of in vivo interaction can be predicted based on the [I] in,max,u /K i ratio.
The relationship between the [I] max,u /K i ratio and the degree of in vivo interaction is summarized in Table 4 . The calculated [I] max,u /K i ratios were less than 0.25 for about 90% of the drugs and about 30% of the drugs in this category were reported to cause in vivo interactions with more than a 1.25-fold increase in the AUC. Furthermore, the [I] max,u /K i ratio was calculated to be less than 0.25 for half of the drugs reported to cause in vivo interactions with more than a 5-fold increase in the AUC. Therefore, predictions using [I] max,u instead of [I] in,max,u may cause substantial underestimation of in vivo interactions. 
